Shots:
- Followed by HC’s approval in Aug 2022, Lupin with its partner Sandoz launched Rymti (biosimilar, Enbrel) in Canada
- The study showed that Rymti has equivalent safety and efficacy to Enbrel. It is a solution for injection in the form of a pre-filled pen & pre-filled syringe
- Rymti is intended to treat children and adolescents with moderate to severe active RA, juvenile idiopathic arthritis, active and progressive Pso arthritis, severe axial spondyloarthritis, moderate to severe plaque Pso, and chronic severe plaque Pso
Ref: Lupin | Image: Lupin & Sandoz| Press Release
Related News:- The US FDA Approves High Concentration of Boehringer Ingelheim’s Cyltezo (Biosimilar, Humira)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
